Dr. Yasenchak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
520 Country Club Pkwy
Eugene, OR 97401Phone+1 541-683-5001Fax+1 541-683-1422
Summary
- I am a board certified hematologist and medical oncologist with a special interest in clinical trials, phase I-III. My practice is largely centered around lymphoma, myeloma and gastrointestinal cancers.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003 - 2006
Johns Hopkins UniversityFellowship, Allergy and Immunology, 2002 - 2003- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Pennsylvania State University College of MedicineClass of 1999
Certifications & Licensure
OR State Medical License 2006 - 2025
WA State Medical License 2006 - 2015
MN State Medical License 2000 - 2010- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Portland Monthly Magazine Castle Connolly, 2011
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
- Join now to see all
Publications & Presentations
PubMed
- 1035 citationsDaratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San-Miguel, Nizar J. Bahlis
The New England Journal of Medicine. 2016-10-05 - 97 citationsPhase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome H. Goldschmidt, Robert T. Chen, Gregg Olsen
Blood. 2015-12-24 - 63 citationsFrontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W. Friedberg, Andres Forero-Torres, Rodolfo Bordoni, Vivian Jean M. Cline, Dipti Patel Donnelly
Blood. 2017-12-28
Journal Articles
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
- An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell LymphomaJeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology
Authored Content
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018
Press Mentions
US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and ExpositionDecember 5th, 2019
Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCLDecember 22nd, 2015
More Treatment-Guiding Interim PET-CT Scans Needed in Advanced Stage Hodgkin LymphomaDecember 4th, 2023
Committees
- PI/SubI, Phase I Research Program. US Oncology Research. 2013 - Present
- PI/SubI, Hematology Research Program. US Oncology Research. 2008 - Present
Research History
- Associate Chair, Hematology Research Program. US Oncology Research2013 - Present
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
